ECSP003528A - Antagonistas del receptor de il - 8 vi - Google Patents

Antagonistas del receptor de il - 8 vi

Info

Publication number
ECSP003528A
ECSP003528A EC2000003528A ECSP003528A ECSP003528A EC SP003528 A ECSP003528 A EC SP003528A EC 2000003528 A EC2000003528 A EC 2000003528A EC SP003528 A ECSP003528 A EC SP003528A EC SP003528 A ECSP003528 A EC SP003528A
Authority
EC
Ecuador
Prior art keywords
antagonists
receiver
chemokine
interleukin
formula
Prior art date
Application number
EC2000003528A
Other languages
English (en)
Inventor
Katherine L Widdowson
John G Gleason
Gregory M Benson
Deborah L Bryan
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of ECSP003528A publication Critical patent/ECSP003528A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a nuevos compuestos de la fórmula (I), a composiciones farmacéuticas y a su uso en el tratamiento de enfermedades mediadas por la quimioquina interleuquina-8(IL)-8.
EC2000003528A 1999-06-16 2000-08-14 Antagonistas del receptor de il - 8 vi ECSP003528A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13967499P 1999-06-16 1999-06-16

Publications (1)

Publication Number Publication Date
ECSP003528A true ECSP003528A (es) 2002-01-25

Family

ID=22487784

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2000003525A ECSP003525A (es) 1999-06-16 2000-06-12 Antagonistas del receptor de il- 8 iv
EC2000003528A ECSP003528A (es) 1999-06-16 2000-08-14 Antagonistas del receptor de il - 8 vi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EC2000003525A ECSP003525A (es) 1999-06-16 2000-06-12 Antagonistas del receptor de il- 8 iv

Country Status (22)

Country Link
EP (1) EP1191934A4 (es)
JP (1) JP2003501471A (es)
KR (1) KR20020009635A (es)
CN (1) CN1494424A (es)
AR (1) AR029368A1 (es)
AU (1) AU766086B2 (es)
BR (1) BR0010985A (es)
CA (1) CA2377397A1 (es)
CZ (1) CZ20014490A3 (es)
EC (2) ECSP003525A (es)
HK (1) HK1044716A1 (es)
HU (1) HUP0202019A3 (es)
IL (1) IL146214A0 (es)
MX (1) MXPA01013287A (es)
NO (1) NO20016065D0 (es)
NZ (1) NZ515232A (es)
PE (1) PE20010319A1 (es)
PL (1) PL352218A1 (es)
TR (1) TR200103690T2 (es)
UY (1) UY26209A1 (es)
WO (1) WO2000076516A1 (es)
ZA (1) ZA200110203B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642215B2 (en) * 2001-05-24 2003-11-04 Leo Pharma A/S Method of modulating NF-kB activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0344425B1 (en) * 1988-03-30 1993-12-08 Warner-Lambert Company N-[[(2,6-disubstituted)phenyl]-N'- arylalkyl] ureas as antihypercholesterolemic and antiatherosclerotic agents
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
AR008290A1 (es) * 1996-08-15 1999-12-29 Smithkline Beecham Corp Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.

Also Published As

Publication number Publication date
AU5748200A (en) 2001-01-02
ZA200110203B (en) 2002-09-11
IL146214A0 (en) 2002-07-25
JP2003501471A (ja) 2003-01-14
NO20016065L (no) 2001-12-12
TR200103690T2 (tr) 2002-05-21
UY26209A1 (es) 2000-12-29
MXPA01013287A (es) 2002-06-04
PE20010319A1 (es) 2001-05-24
BR0010985A (pt) 2002-03-26
WO2000076516A1 (en) 2000-12-21
HUP0202019A2 (en) 2002-10-28
NO20016065D0 (no) 2001-12-12
AR029368A1 (es) 2003-06-25
HUP0202019A3 (en) 2003-03-28
EP1191934A1 (en) 2002-04-03
AU766086B2 (en) 2003-10-09
HK1044716A1 (zh) 2002-11-01
ECSP003525A (es) 2002-01-25
CA2377397A1 (en) 2000-12-21
PL352218A1 (en) 2003-08-11
NZ515232A (en) 2004-02-27
CZ20014490A3 (cs) 2002-07-17
KR20020009635A (ko) 2002-02-01
EP1191934A4 (en) 2004-02-04
CN1494424A (zh) 2004-05-05

Similar Documents

Publication Publication Date Title
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
ATE419845T1 (de) Il-8-rezeptor-antagonisten
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
UY26601A1 (es) Antagonistas de los receptores de il-8
PA8579601A1 (es) Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
MY133845A (en) Il-8 receptor antagonists
NZ514696A (en) IL-8 receptor antagonists
AP1548A (en) Il-8 Receptor Antagonists.
ECSP066474A (es) Arilindenopiridinas y arilindenopirimidinas y su uso como antagonista del receptor adenosina a2a
WO2001068569A3 (en) Il-8 receptor antagonists
BR0010843A (pt) Antagonistas de receptores de il-8
MY143477A (en) Il-8 receptor antagonists
AP2002002606A0 (en) INTERLEUKIN 8 RECEPTOR ANTAGONISTS
BR0010863A (pt) Antagonistas de receptores de il-8
WO2001064165A3 (en) Il-8 receptor antagonists
WO2001076530A3 (en) Il-8 receptor antagonists
ECSP003527A (es) Antagonistas del receptor de il - 8 v
UY26209A1 (es) Antagonistas de los receptores de la il-8.
WO2001068033A3 (en) Il-8 receptor antagonists
ECSP003529A (es) Antagonistas del receptor de il - 8 vii
UY26206A1 (es) Antagonistas del receptor de il-8.
WO2001068570A3 (en) Il-8 receptor antagonists
BR9815951A (pt) Antagonistas do receptor de il-8
AP2001002178A0 (en) IL-8 receptor antagonists.